Replies to post #1005 on Armata Pharmaceuticals, Inc. (ARMP)

[gator16]

MORE GOOD NEWS !!!!


September 11, 2017, 6:50 am EDT

AmpliPhi Biosciences Announces First Intravenous Treatment of a Patient with AB-SA01 Targeting Staphylococcus aureus
SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces the first-in-human intravenous administration of AmpliPhi’s drug candidate AB-SA01. AmpliPhi supplied AB-SA01 to a major hospital in Australia for a patient suffering from a life-threatening Staphylococcus aureus (S. aureus) infection of the heart (endocarditis). AB-SA01 was administered intravenously to the patient over two weeks and was well tolerated.

Read Full Release

--
If you no longer wish to receive alerts from Official Investor News from AmpliPhi Biosciences, update your alert settings here: http://investor.ampliphibio.com/alerts

________________________________________